Notably, four peptides SILDIVTKV (RFTN2), AIIDGVESV (PTPRZ1), KVFAGIPTV (PTPRZ1), and NLDTLMTYV (NLGN4X) (Supplementary Table 2) were also reported as immunogenic in patients with GBM providing strong evidence that these peptides should also be explored in patients with HLA-A2+ DIPG (29, 56). This evidence concerns the gene RFTN2 and glioblastoma.